Targets GIP + GLP-1 receptors for synergistic effects on insulin secretion, appetite suppression, and metabolic improvement
SLU-PP-332 has well defined molecular properties for research use
Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Munoz D, Smith SC Jr., Virani SS, Williams KA Sr., Yeboah J, Ziaeian B
The metabolic effects that promote glucose uptake acutely can, with chronic exposure, lead to cells becoming less responsive to insulin's signals
It is essential to note that retatrutide remains an investigational drug